BRAF Inhibitor Resistance Confers Increased Sensitivity to Mitotic Inhibitors

Single agent and combination therapy with BRAF(V600E/K) and MEK inhibitors have remarkable efficacy against melanoma tumors with activating BRAF mutations, but in most cases BRAF inhibitor (BRAFi) resistance eventually develops. One resistance mechanism is reactivation of the ERK pathway. However, o...

Descripción completa

Detalles Bibliográficos
Autores principales: Misek, Sean A., Foda, Bardees M., Dexheimer, Thomas S., Akram, Maisah, Conrad, Susan E., Schmidt, Jens C., Neubig, Richard R., Gallo, Kathleen A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015667/
https://www.ncbi.nlm.nih.gov/pubmed/35444937
http://dx.doi.org/10.3389/fonc.2022.766794

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015667/
https://www.ncbi.nlm.nih.gov/pubmed/35444937
http://dx.doi.org/10.3389/fonc.2022.766794

Ejemplares similares